Pfizer (PFE) Offering Possible 7.53% Return Over the Next 13 Calendar Days

Pfizer's most recent trend suggests a bullish bias. One trading opportunity on Pfizer is a Bull Put Spread using a strike $36.00 short put and a strike $31.00 long put offers a potential 7.53% return on risk over the next 13 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $36.00 by expiration. The full premium credit of $0.35 would be kept by the premium seller. The risk of $4.65 would be incurred if the stock dropped below the $31.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Pfizer is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Pfizer is bullish.

The RSI indicator is at 65.96 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Pfizer

Is Pfizer Giving Its Partner BioNTech the Shaft by Developing mRNA Vaccines on Its Own?
Fri, 02 Apr 2021 11:03:00 +0000
Pfizer (NYSE: PFE) CEO Albert Bourla recently stated in an interview with The Wall Street Journal that the big drugmaker plans to develop messenger RNA (mRNA) vaccines on its own going forward. In this Motley Fool Live video recorded on March 24, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Pfizer's move could hurt its smaller partner.

UPDATE 1-Bulgaria to receive ‘solidarity' vaccines, says PM
Fri, 02 Apr 2021 10:17:51 +0000
Bulgaria will receive more than 1.2 million additional doses of COVID-19 vaccine produced by BioNTech and Pfizer in the second quarter, Prime Minister Boyko Borissov said on Friday. Most European Union member states agreed late on Thursday to share part of 10 million BioNTech-Pfizer vaccine deliveries with Bulgaria, Croatia, Estonia, Latvia and Slovakia, countries they said were most in need. But Czech Prime Minister Andrej Babis on Friday criticized that deal as unbalanced, saying he did not understand how the European Union could agree on such a plan when the Czech Republic, Austria and Slovenia opposed it, he told CTK news agency.

Thinking About Buying AMC and GameStop? These 2 Robinhood Stocks Are Much Better Picks
Fri, 02 Apr 2021 10:01:00 +0000
It's no wonder that AMC Entertainment (NYSE: AMC) and GameStop (NYSE: GME) remain wildly popular with Robinhood investors. You could call AMC and GameStop FOMO stocks. One key argument for buying shares of GameStop is that the company hopes to transform itself from a brick-and-mortar retailer to an online gaming giant.

Bulgaria to receive ‘solidarity' vaccines, says PM
Fri, 02 Apr 2021 06:48:09 +0000
Most European Union member states agreed late on Thursday to share part of 10 million BioNTech-Pfizer vaccine deliveries with Bulgaria, Croatia, Estonia, Latvia and Slovakia, countries they said were most in need. Bulgaria, which has the slowest inoculation rate in the EU, will receive 1.26 million doses out of 2.85 million so-called “solidarity vaccines” for the five EU members.

Blood clots and the AstraZeneca Covid vaccine: is there a link?
Fri, 02 Apr 2021 00:00:00 +0000
Two weeks after the European Medicines Agency first assured EU member states it had found no link between the Oxford/AstraZeneca vaccine and earlier reports of rare blood clots, a growing number of countries have announced new restrictions on the use of the jab. While the UK and Austria have imposed no curbs, France, Sweden, Finland, Canada and most recently Germany have recommended that younger people avoid the shot. The EMA, the World Health Organization and the UK’s Medicines and Healthcare products Regulatory Agency all state that the benefits of the vaccine outweigh any possible risks.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.